ClinicalTrials.gg
CompletedNCT03751007Updated Feb 1, 2023Results posted

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

A Phase 1/2 interventional study of AG019 - Low Dose and Teplizumab in Diabetes type1, sponsored by Precigen Actobio T1D, LLC. Completed at 18 sites in 2 countries. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by Precigen Actobio T1D, LLC · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Enrollment
7th of 11
45 · median 60
Started
2018
the only one that year
Phase 1/2
Only one
of the 11
Registered
5th of 11
by date
Lead sponsor
1 of 11
Precigen Actobio T1D, LLC

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 7th largest by enrollment, is the only one that started in 2018, is the only one in phase 1/2, and was the 5th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants with recent-onset type 1 diabetes (T1D).

Read the detailed description

This Phase 1b/2a, multi-center study will be conducted in participants with clinical recent-onset type 1 diabetes (T1D).

The primary objective of this study is to assess the safety and tolerability of different doses of AG019 alone as well as AG019 in combination with teplizumab. The secondary objectives of this study are: to obtain pharmacodynamic (PD) data of AG019 alone as well as AG019 in combination with teplizumab; and to determine the potential presence of AG019 in systemic circulation (safety - systemic exposure) and the presence of L. lactis bacteria in fecal excretion (local exposure): Pharmacokinetic (PK) profile.

This study consists of 2 phases:

Phase 1b: this open-label part of the study will investigate the safety and tolerability of 2 different doses of AG019 in 2 age groups (18-40 years of age and 12-17 years of age).

Phase 2a: this randomized, double-blind part of the study will investigate the safety and tolerability of AG019, in combination with teplizumab, in 2 age groups (18-40 years of age and 12-17 years of age).

03

Conditions studied

  • Diabetes type1
04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-lactating females, 18 - 40 years of age (both inclusive) or 12-17 years of age (both inclusive)
  • Diagnosis of diabetes according to the American Diabetes Association (ADA) recommended criteria
  • Evidence of auto-antibodies to at least 1 β-cell autoantigen
  • Stimulated C-peptide measured during 4h Mixed Meal tolerance Test (MMTT) > 0.2 nmol/L
  • The first administration of AG019 should occur no later than 150 days post diagnosis of diabetes
  • Body weight ≥ 33kg
  • Written obtained and documented (participant, parent, guardian as applicable)

Exclusion criteria

Exclusion Criteria:

  • Previous history of serious cytokine release syndrome to teplizumab or other humanized anti-CD3 monoclonal antibodies with no or minimal capacity to bind Fc receptors. (Participants enrolled in the second phase of the trial in either Combination Cohort 1 or Combination Cohort 2, only)
  • Use of or immunomodulatory therapies, including systemic within 1 month prior to randomization
  • Participation in another drug trial within 12 weeks prior to the first study drug intake and during participation in this study
  • History of recurrent infections, other diseases, cardiac disease, , or any other (chronic) medical condition which, in the investigator's opinion, could compromise participant safety
  • Documented history of (HIV), Hepatitis Virus Type C (), Hepatitis Virus Type B () infection
  • Evidence of active infection with Epstein-Barr Virus (EBV) or cytomegalovirus (CMV)
  • Evidence of active or latent tuberculosis (TB)
  • Administration of anti-CD3 antibody in past year
  • Current therapy with any other anti-diabetic agents other than insulin (MDI, CSII or analogue). Current or planned therapy with experimental (i.e., unapproved) insulin. Patients on therapy for type 2 diabetes (e.g. metformin) should stop their therapy in order to be eligible for study participation.
  • Use of medications known to influence glucose tolerance
  • Daily use of non-steroidal anti-inflammatory agents
  • Compromised GI mucosal integrity or motility, not attributable to T1D (i.e., recent diarrhea, gluten sensitive enteropathy, inflammatory bowel disease, irritable bowel syndrome), or current use of medications known to influence GI motility
  • Positive result of SARS-Cov2 PCR test at screening or within 3 days before randomization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    AG019 Cohort 1 - Low Dose/Adults

    Biological: AG019 - Low Dose

  • Experimental
    AG019 Cohort 2 - High Dose/Adults

    Biological: AG019 - High Dose

  • Experimental
    AG019 Cohort 3 - Low Dose/Adolescents

    Biological: AG019 - Low Dose

  • Experimental
    AG019 Cohort 4 - High Dose/Adolescents

    Biological: AG019 - High Dose

  • Experimental
    Combination Cohort 1 - Adults

    Drug: Teplizumab · Drug: Placebo-AG019 · Drug: Placebo-Teplizumab · Biological: AG019 - High Dose

  • Experimental
    Combination Cohort 2 - Adolescents

    Drug: Teplizumab · Drug: Placebo-AG019 · Drug: Placebo-Teplizumab · Biological: AG019 - High Dose

Interventions

  • BiologicalAG019 - Low Dose

    Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)

  • Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).

  • DrugPlacebo-AG019

    Formulated identically to AG019 with the active ingredient removed.

  • DrugPlacebo-Teplizumab

    Formulated identically to teplizumab with the active ingredient removed.

  • BiologicalAG019 - High Dose

    Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks

  • BiologicalAG019 - High Dose

    Solid, orally administered capsule - 6 capsules per day for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAE)

    Treatment-emergent adverse events assessed by the investigator, review of lab reports and information provided by the participant during site visits and/or participant diary with AG019 alone or with teplizumab

    Time frame: up to 6 months

Secondary outcomes

  1. AG019 in Systemic Circulation

    The presence of live L. lactis bacteria in blood will be assessed by plating

    Time frame: Up to 3 months after initiation of the treatment

  2. L. Lactis-secreted hPINS or hIL-10 in Systemic Circulation

    The presence of L. lactis-secreted hPINS or hIL-10 in the blood will be assessed by ELISA (enzyme-linked immunosorbent assay)

    Time frame: Up to 3 months after initiation of the treatment

  3. AG019 in Feces

    The presence of L. lactis (live or dead) in feces will be assessed by Q-PCR (quantitative real-time polymerase chain reaction)

    Time frame: Up to 8 days after completion of the treatment

  4. C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months

    MMTT-stimulated 2-hour C-peptide AUC was defined as the mean area under the C-peptide level time curve over the 2-hour period divided by the duration after a mixed-meal tolerance test.

    Time frame: up to 12 months

Other outcomes

  1. Incidence of Treatment Emergent Adverse Events up to 12 Months

    Incidence of all reported TEAE up to the 12-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.

    Time frame: Up to 12 months from screening

07

Results

Posted Feb 1, 2023

Participant flow

AG019 monotherapy cohorts: a total of 8 single dose patients and 19 repeat dose patients. AG019/teplizumab combination cohorts: a total of 18 patients

Participant flow — Overall Study
MilestoneAG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents
Started2525242510251
Completed2524242410240
Not completed000100010011

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events (TEAE)

Treatment-emergent adverse events assessed by the investigator, review of lab reports and information provided by the participant during site visits and/or participant diary with AG019 alone or with teplizumab

Time frame:
up to 6 months
Reported as:
Number · Events
Incidence of Treatment-emergent Adverse Events (TEAE)
EventsAG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents
Incidence of Treatment-emergent Adverse Events (TEAE)161191281199125221
SecondaryAG019 in Systemic Circulation

The presence of live L. lactis bacteria in blood will be assessed by plating

Time frame:
Up to 3 months after initiation of the treatment
Reported as:
Count of participants · Participants
AG019 in Systemic Circulation
ParticipantsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents
AG019 in Systemic Circulation00000000
SecondaryL. Lactis-secreted hPINS or hIL-10 in Systemic Circulation

The presence of L. lactis-secreted hPINS or hIL-10 in the blood will be assessed by ELISA (enzyme-linked immunosorbent assay)

Time frame:
Up to 3 months after initiation of the treatment
Reported as:
Count of participants · Participants
L. Lactis-secreted hPINS or hIL-10 in Systemic Circulation
ParticipantsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents
L. Lactis-secreted hPINS or hIL-10 in Systemic Circulation00000000
SecondaryAG019 in Feces

The presence of L. lactis (live or dead) in feces will be assessed by Q-PCR (quantitative real-time polymerase chain reaction)

Time frame:
Up to 8 days after completion of the treatment
Reported as:
Count of participants · Participants
AG019 in Feces
ParticipantsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents
participants with AG019 in feces339030
participants with no AG019 in feces211201
SecondaryC-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months

MMTT-stimulated 2-hour C-peptide AUC was defined as the mean area under the C-peptide level time curve over the 2-hour period divided by the duration after a mixed-meal tolerance test.

Time frame:
up to 12 months
Reported as:
Mean · nmol/L
C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months
nmol/LAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsAG019 Cohort 1 - Low (Repeat)-Dose/AdultsAG019 Cohort 3 - Low (Repeat) Dose/Adolescents
C-peptide Area Under the Concentration-time Curve (AUC) Calculated From a 2 Hour Mixed Meal Tolerance Test (MMTT) at 12 Months0.89 ± 0.610.57 ± 0.130.48 ± 0.190.73 ± 0.010.57 ± 0.210.25 ± 00.62 ± 0.480.78 ± 0.35
Other pre-specifiedIncidence of Treatment Emergent Adverse Events up to 12 Months

Incidence of all reported TEAE up to the 12-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.

Time frame:
Up to 12 months from screening
Reported as:
Number · events
Incidence of Treatment Emergent Adverse Events up to 12 Months
eventsAG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents
Incidence of Treatment Emergent Adverse Events up to 12 Months181261331269726232

Adverse events

Collected over Adverse events were collected from signature of informed consent until completion of the study (or premature withdrawal), an average of 13 months (1 month of screening plus 12 months of study participation).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG019 Cohort 1 - Low (Single) Dose/Adults0/2 (0%)0/2 (0%)1/2 (50%)
AG019 Cohort 1 - Low (Repeat) Dose/Adults0/5 (0%)0/5 (0%)3/5 (60%)
AG019 Cohort 2 - High (Single) Dose/Adults0/2 (0%)0/2 (0%)1/2 (50%)
AG019 Cohort 2 - High (Repeat) Dose/Adults0/5 (0%)0/5 (0%)2/5 (40%)
AG019 Cohort 3 - Low (Single) Dose/Adolescents0/2 (0%)0/2 (0%)1/2 (50%)
AG019 Cohort 3 - Low (Repeat) Dose/Adolescents0/4 (0%)0/4 (0%)2/4 (50%)
AG019 Cohort 4 - High (Single) Dose/Adolescents0/2 (0%)0/2 (0%)1/2 (50%)
AG019 Cohort 4 - High (Repeat) Dose/Adolescents0/5 (0%)0/5 (0%)2/5 (40%)
Combination Cohort 1 - Active AG019/Teplizumab - Adults0/10 (0%)0/10 (0%)5/10 (50%)
Combination Cohort 1 - AG019-placebo/Teplizumab-placebo - Adults0/2 (0%)0/2 (0%)2/2 (100%)
Combination Cohort 2 - Active AG019/Teplizumab - Adolescents0/5 (0%)0/5 (0%)2/5 (40%)
Combination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 151
Most frequent other events
EventAG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - Adolescents
Iron deficiency anaemiaBlood and lymphatic system disorders0/20/50/20/50/20/40/20/50/102/20/50/1
HeadacheNervous system disorders0/20/50/21/50/20/40/21/55/102/21/50/1
AnxietyPsychiatric disorders0/20/50/20/50/20/40/21/51/100/21/51/1
Attention deficit hyperactivity disorderPsychiatric disorders0/20/50/20/50/20/40/20/50/100/21/51/1
Upper respiratory tract infectionInfections and infestations0/23/50/21/50/22/40/22/51/100/20/50/1
LeukopeniaBlood and lymphatic system disorders0/20/50/21/50/22/40/22/52/100/20/50/1
LymphadenopathyBlood and lymphatic system disorders0/20/50/20/50/22/40/20/51/100/20/50/1
Sinus bradycardiaCardiac disorders0/20/50/20/50/20/41/20/50/100/20/50/1
VertigoEar and labyrinth disorders0/20/50/20/50/20/40/20/50/101/20/50/1
Abdominal discomfortGastrointestinal disorders0/20/50/20/50/20/40/20/50/101/20/50/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Median38.0 ± 5.726.0 ± 8.919.5 ± 2.122.0 ± 7.416.5 ± 0.714.0 ± 2.217.0 ± 0.014.0 ± 1.926.5 ± 6.729.0 ± 5.714.0 ± 1.112.0 ± 0.020.0 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Female01122203413120
Male24130222612025
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Hispanic or Latino0011001000003
Not Hispanic or Latino251424151025142
Unknown or Not Reported0000000000000
Baseline serological cytomegalovirus positivity
Baseline serological cytomegalovirus positivity(Participants)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Negative25252325514137
Positive0000010051007
Missing0000000000101
Baseline serological Epstein-Barr virus positivity
Baseline serological Epstein-Barr virus positivity(Participants)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Negative22242424404131
Positive03010001621014
Autoantibody positivity - GAD65
Autoantibody positivity - GAD65(Participants)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Negative0000010000203
Positive152513151023139
Missing1000101000003
Autoantibody positivity - IA-2
Autoantibody positivity - IA-2(Participants)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Negative12110202511016
Positive02141202314121
Missing1100102120008
Autoantibody positivity - ZnT8
Autoantibody positivity - ZnT8(Participants)AG019 Cohort 1 - Low (Single) Dose/AdultsAG019 Cohort 1 - Low (Repeat) Dose/AdultsAG019 Cohort 2 - High (Single) Dose/AdultsAG019 Cohort 2 - High (Repeat) Dose/AdultsAG019 Cohort 3 - Low (Single) Dose/AdolescentsAG019 Cohort 3 - Low (Repeat) Dose/AdolescentsAG019 Cohort 4 - High (Single) Dose/AdolescentsAG019 Cohort 4 - High (Repeat) Dose/AdolescentsCombination Cohort 1 - Active AG019/Teplizumab - AdultsCombination Cohort 1 - AG019-placebo/Teplizumab-placebo - AdultsCombination Cohort 2 - Active AG019/Teplizumab - AdolescentsCombination Cohort 2 - AG019-placebo/Teplizumab-placebo - AdolescentsTotal
Negative0012010120007
Positive12120303503020
Missing13012021322118

9 further baseline measures are reported on the registry.

08

Study locations

18 sites
  • University of Alabama, Birmingham
    Birmingham, Alabama 35294, United States
  • University of California, San Francisco
    San Francisco, California 94158, United States
  • Coastal Metabolic Research Centre
    Ventura, California 93003, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Yale Center for Clinical Investigation
    New Haven, Connecticut 06519, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Barry J Reiner, MD, LLC
    Baltimore, Maryland 21229, United States
  • University of Minnesota Health
    Minneapolis, Minnesota 55454, United States
  • University of Missouri-Kansas City School of Medicine
    Kansas City, Missouri 64108, United States
  • Sanford Children's Specialty Clinic
    Sioux Falls, South Dakota 57117, United States
  • University Diabetes and Endocrine Consultants
    Chattanooga, Tennessee 37411, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78749, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Benaroya Research Institute
    Seattle, Washington 98101, United States
  • UZ Brussel
    Brussels, 1090, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Oct 2021, 35 months.

Results were first posted in Feb 2023, 1 year 3 months after primary completion.

Of 44 phase 1/2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 93. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2018
First posted
Nov 23, 2018
StartActual
Oct 24, 2018
Primary completionActual
Oct 13, 2021
CompletionActual
Oct 13, 2021
Results first posted
Feb 1, 2023
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03751007
Lead sponsor
Precigen Actobio T1D, LLC
Collaborators
Intrexon Actobiotics NV, d/b/a Precigen Actobio
Responsible party
Sponsor
First posted
Nov 23, 2018
Start date
Oct 24, 2018
Primary completion
Oct 13, 2021
Completion
Oct 13, 2021
Results posted
Feb 1, 2023
Last update
Feb 1, 2023

Study contacts

Chantal Mathieu, MD
principal investigator · University Hospital of Leuven, Clinical and Experimental Endocrinology
Kevan Herold, MD
principal investigator · Yale Center for Clinical Investigation; Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion